Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)

INTERVENTION: experimental group:Xiyanping injection;control group:alpha‐interferon; CONDITION: novel coronavirus pneumonia (COVID‐19) PRIMARY OUTCOME: vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes; SECONDARY OUTCOME: Hemodiafiltration;Mechanical ventilation time;Application of pulmonary surfactant;Oxygen time (hours);ICU days; INCLUSION CRITERIA: 1. 18 years old <= age <= 60 years old at the time of screening; 2. Pharyngeal swabs, alveolar lavage fluid, or sputum specimens during screening showed that 2019‐nCoV virus nucleic acid test results were positive for at least two of nCov‐EP, nCov‐NP, and nCovORF1ab, in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment plan (trial version 5); 3. The investigator determined that aerosolized inhalation treatment was appropriate, and volunteered to participate in the study and signed informed consent.